Comparative Pharmacology
Head-to-head clinical analysis: JUNIOR STRENGTH MOTRIN versus SPRIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNIOR STRENGTH MOTRIN versus SPRIX.
JUNIOR STRENGTH MOTRIN vs SPRIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
Intranasal: 31.5 mg (1 spray) in one nostril, may repeat after 30 minutes; maximum 63 mg (2 sprays) per dose. Subsequent doses every 6-8 hours as needed; maximum 126 mg (4 sprays) per day.
None Documented
None Documented
1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia.
Terminal elimination half-life is 5-6 hours in adults with normal renal function; may be prolonged to 13-14 hours in elderly patients and 15-20 hours in patients with renal impairment.
Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%).
Renal excretion of unchanged drug and metabolites; after intravenous administration, approximately 92% of the dose is recovered in urine (50% as unchanged ketorolac, 40% as glucuronide conjugates) and 6% in feces.
Category C
Category C
NSAID Analgesic
NSAID Analgesic